Log in

2659 Shanghai Bao Pharmaceuticals Co Ltd HKEX · China

Shanghai Bao Pharmaceuticals Co (2659) news

Shanghai Bao Pharmaceuticals Co Ltd is a public biotech or pharmaceutical company listed on HKEX under the ticker 2659, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Shanghai Bao Pharmaceuticals Co news

We have not published a story on Shanghai Bao Pharmaceuticals Co yet. When there is news, it will appear here.

Questions about Shanghai Bao Pharmaceuticals Co

What is the ticker symbol of Shanghai Bao Pharmaceuticals Co?

Shanghai Bao Pharmaceuticals Co Ltd trades under the ticker 2659 on HKEX.

Where is Shanghai Bao Pharmaceuticals Co listed?

Shanghai Bao Pharmaceuticals Co Ltd is listed on HKEX.

Which country or territory is Shanghai Bao Pharmaceuticals Co listed under?

Our directory records Shanghai Bao Pharmaceuticals Co Ltd under China.

What does Shanghai Bao Pharmaceuticals Co do?

Our directory classifies Shanghai Bao Pharmaceuticals Co Ltd as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Shanghai Bao Pharmaceuticals Co?

The ISIN recorded for Shanghai Bao Pharmaceuticals Co Ltd is CNE100007B92.

Does aibio.space cover Shanghai Bao Pharmaceuticals Co?

aibio.space lists Shanghai Bao Pharmaceuticals Co Ltd among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Shanghai Bao Pharmaceuticals Co?

Companies in our directory listed in the same country and business area as Shanghai Bao Pharmaceuticals Co: Shanghai Junshi Biosciences Co., Zhejiang Yatai Pharmaceutical Co., Shanghai Jiaoda Onlly Co., Jinling Pharmaceutical Co., Yili Chuanning Biotechnology Co., Anhui Sunhere Pharmaceutical Excipients Co..

Investor discussion: Shanghai Bao Pharmaceuticals Co

Members talk about Shanghai Bao Pharmaceuticals Co (2659). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Shanghai Bao Pharmaceuticals Co, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: CIRCULAR OF ANNUAL GENERAL MEETING. Source

  2. Financings

    Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of Shanghai Bao Pharmaceuticals Co's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT - IND FOR BJ045 FOR INJECTION WAS APPROVED BY NMPA

  2. HKEXnews

    Terms of Reference for the Nomination Committee of the Board of Directors

  3. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT - IND FOR SUBCUTANEOUS INFUSION OF KJ015 FOR INJECTION (SC) WAS APPROVED BY U.S. FDA

  5. HKEXnews

    CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT; AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT - NMPA APPROVAL OF IND APPLICATION FOR BJ044 INJECTION (RECOMBINANT ULINASTATIN)

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT - IND FOR SUBCUTANEOUS INFUSION OF BJ007 FOR INJECTION (SC) WAS APPROVED BY U.S. FDA

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR KJ103 FOR INJECTION BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

  9. HKEXnews

    Articles of Association

  10. HKEXnews

    (1) POLL RESULTS OF THE RESOLUTION PROPOSED AT THE ANNUAL GENERAL MEETING HELD ON MAY 26, 2026 (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ABOLISHMENT OF THE BOARD OF SUPERVISORS (3) RE-ELECTION AND APPOINTMENT OF DIRECTORS (4) APPOINTMENT OF CHAIRMAN OF THE SECOND SESSION OF THE BOARD (5) ELECTION OF THE EMPLOYEE REPRESENTATIVE DIRECTOR AND (6) CHANGE IN COMPOSITION OF BOARD COMMITTEES

  11. HKEXnews

    NOTICE OF ANNUAL GENERAL MEETING

  12. HKEXnews

    CIRCULAR OF ANNUAL GENERAL MEETING

  13. HKEXnews

    VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS AND PROPOSED SHAREHOLDING INCREASE BY CONTROLLING SHAREHOLDER AND INTENTION TO PROPOSE SHARE REPURCHASE MANDATE

  14. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HUMAN HYALURONIDASE FOR INJECTION APPROVED FOR MARKETING BY THE NMPA

  15. HKEXnews

    PROPOSED ELECTION OF DIRECTORS OF THE SECOND SESSION OF THE BOARD AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  16. HKEXnews

    ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

  17. HKEXnews

    VOLUNTARY ANNOUNCEMENT - COMPLETION OF PHASE III CLINICAL TRIAL FOLLOW-UP OF KJ103 FOR DESENSITIZATION IN KIDNEY TRANSPLANTATION

  18. HKEXnews

    VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPROVAL FOR NEW INDICATION OF KJ101

  19. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE STOCK LIST UNDER THE STOCK CONNECT

  20. HKEXnews

    Notification Letter and Reply Form to Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2659 on TradingView.

Listing details

Shanghai Bao Pharmaceuticals Co Ltd is a public biotech or pharmaceutical company listed on HKEX under the ticker 2659, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Shanghai Bao Pharmaceuticals Co Ltd
Ticker
2659
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
CNE100007B92
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.